The World Health Organization (WHO) today announced recommendations for the viral composition of influenza vaccines for the 2022-2023 flu season in the northern part of the world. The announcement was made at an information meeting at the end of a 4-day information meeting on the composition of the influenza vaccine, which took place twice a year.

The WHO organized this consultation with an advisory group of experts gathered from the WHO Collaboration Centers and the WHO Core Regulatory Laboratories to analyze influenza virus monitoring data generated by the WHO Global Influenza Surveillance System. . The issued recommendations are used by national vaccine regulators and pharmaceutical companies to manufacture, manufacture and license influenza vaccines for the next flu season.

For vaccines to be effective, regular updates of the viruses present in the influenza vaccine are needed due to the ever-evolving nature of influenza viruses, including those that circulate and circulate. The WHO recommends that the quadrivalent vaccines used during the 2022-2023 influenza season in the northern part of the world have the following:

+ Egg-based faxes

- in A / Victoria / 2570/2019 (H1N1) virus similar to pdm09;

- in A / Darwin / 9/2021 (H3N2) similar virus;

- a similar virus in B / Austria / 1359417/2021 (B / Victoria lineage); en

- a similar virus in B / Phuket / 3073/2013 (B / Yamagata line).

+ Cell culture-based vaccines as recombinant

- in A / Wisconsin / 588/2019 (H1N1) virus similar to pdm09;

- in A / Darwin / 6/2021 (H3N2) similar virus;

- a similar virus in B / Austria / 1359417/2021 (B / Victoria lineage); en

- a similar virus in B / Phuket / 3073/2013 (B / Yamagata line)

The WHO recommends that trivalent vaccines used during the 2022-2023 influenza season in the northern part of the world have the following:

+ Egg-based faxes

- in A / Victoria / 2570/2019 (H1N1) virus similar to pdm09;

- in A / Darwin / 9/2021 (H3N2) similar virus; 

- in B / Austria / 1359417/2021 (B / Victoria line) a similar virus.

+ Cell culture-based vaccines as recombinant

- in A / Wisconsin / 588/2019 (H1N1) virus similar to pdm09;

- in A / Darwin / 6/2021 (H3N2) similar virus; 

- in B / Austria / 1359417/2021 (B / Victoria line) a similar virus